Neurofibromatosis type 1 tumour suppressor gene expression is deficient in psoriatic skin in vivo and in vitro: A potential link to increased Ras activity

British Journal of Dermatology

Volumn 150, Issue 2, 2004, Pages 211-219

  Karvonen, S L ^a,b,c   Koivunen, J ^a   Nissinen, M ^a   Yla Outinen H ^a   Bjorkstrand A S ^a   Peltonen, J ^a,d  

^a UNIVERSITY OF OULU   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Neurofibromatosis type 1 tumour suppressor; Neurofibromin; Psoriasis; Ras MAPK

Indexed keywords

MESSENGER RNA; NEUROFIBROMIN;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; PSORIASIS; TUMOR SUPPRESSOR GENE;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; GENE EXPRESSION; GENES, NEUROFIBROMATOSIS 1; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; NEUROFIBROMIN 1; PSORIASIS; RNA, MESSENGER;

EID: 1542611558     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.05767.x     Document Type: Article

References (39)

1. Trembath RC, Clough RL, Rosbotham JL et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6: 813-20.
2. Allen MH, Veal C, Faassen A et al. A non-HLA gene within the MHC in psoriasis. Lancet 1999; 353: 1589-90.
3. Semprini S, Capon F, Bovolenta S et al. Genomic structure, promoter characterisation and mutational analysis of the S100A7 gene: exclusion of a candidate for familial psoriasis susceptibility. Hum Genet 1999; 104: 130-4.
4. Asumalahti K, Laitinen T, Itkonen-Vatjus R et al. A candidate gene for psoriasis near HLA-C, HCR (pg8), is highly polymorphic with a disease-associated susceptibility allele. Hum Mol Genet 2000; 9: 1533-42.
5. Pummi K, Malminen M, Aho H et al. Epidermal tight junctions: ZO-1 and occludin in mature, developing, and affected skin, and in vitro differentiating keratinocytes. J Invest Dermatol 2001; 117: 1050-8.
6. Norris DA, Travers JB, Leung DY. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 1997; 109: 1-4.
7. Nickoloff B. Skin innate immune system in psoriasis: friend or foe? J Clin Invest 1999; 104: 1161-4.
8. Nickoloff B. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-10.
9. Travers JB, Hamid QA, Norris DA et al. Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J Clin Invest 1999; 104: 1181-9.
10. Mondello MR, Magaudda L, Pergolizzi S et al. Behaviour of laminin 1 and type IV collagen in uninvolved psoriatic skin. Immunohistochemical study using confocal laser scanning microscopy. Arch Dermatol Res 1996; 288: 527-31.
11. Fleischmajer R, Kuroda K, Hazan R et al. Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J Invest Dermatol 2000; 115: 771-7.
12. Orfanos CE, Schaumburg-Lever G, Mahrle G et al. Alterations of cell surfaces as a pathogenetic factor in psoriasis. Possible loss of contact inhibition of growth. Arch Dermatol 1973; 107: 38-46.
13. Pellegrini G, Luca M, Orecchia G et al. Expression, topography, and function of integrin receptors are severely altered in keratinocytes from involved and uninvolved psoriatic skin. J Clin Invest 1992; 89: 1783-95.
14. Oyama N, Takahashi H, Tojo M et al. Different properties of three isoforms (alpha, beta, and gamma) of transcription factor AP-2 in the expression of human keratinocyte genes. Arch Dermatol Res 2002; 294: 273-80.
15. Magaudda L, Mondello MR, Vaccaro M et al. Changes in the distribution of actin-associated proteins in psoriatic keratinocytes. Immunohistochemical study using confocal laser microscopy. Arch Dermatol Res 1997; 289: 3378-83.
16. Gutman DH, Wood DL, Collins FS. Identification of the neurofibromatosis type I gene product. Proc Natl Acad Sci USA 1991; 88: 9658-62.
17. Marchuk DA, Saulino AM, Tavakkol R et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 1991; 11: 931-40.
18. Bollag G, McCormick F. NF is enough of GAP. Nature 1992; 356: 663-4.
19. Legius E, Marchuk DA, Collins FS et al. Somatic deletion of the neurofibromatosis type I gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993; 3: 122-6.
20. Li Y, Bollag G, Clark R et al. Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 1992; 69: 275-81.
21. Hermonen J, Hirvonen O, Ylä-Outinen H et al. Neurofibromin: expression by normal human keratinocytes in vivo and in vitro and in epidermal malignancies. Lab Invest 1995; 73: 221-8.
22. Peltonen J, Karvonen S-L, Ylä-Outinen H et al. Lesional psoriatic epidermis displays reduced neurofibromin immunoreactivity. J Invest Dermatol 1995; 105: 664-7.
23. Aaltonen V, Boström PJ, Söderström K-O et al. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of Nf1 tumor suppressor gene in vivo and in vitro. Am J Pathol 1999; 154: 755-65.
24. Levitzki A. Signal transduction therapy: a novel approach to disease management. Eur J Biochem 1994; 226: 1-13.
25. Malumbres M, Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci 1998; 3: d887-912.
26. Lin P, Baldassare JJ, Voorhees JJ et al. Increased activation of Ras in psoriatic lesions. Skin Pharmacol Appl Physiol 1999; 112: 90-7.
27. Kobayashi H, Yasuda H, Ohkawara A et al. Enhanced expression of ras gene products in psoriatic epidermis. Arch Dermatol Res 1988; 280: 259-63.
28. Karvonen S-L, Korkiamäki T, Ylä-Outinen H et al. Psoriasis and altered calcium metabolism: downregulated capacitative calcium influx and defective calcium mediated cell signaling in cultured psoriatic keratinocytes. J Invest Dermatol 2000; 114: 693-700.
29. 2+-induced keratinocyte differentiation. Lab Invest 2001; 82: 353-61.
30. Ylä-Outinen H, Aaltonen V, Björkstrand A-S et al. Up-regulation of tumor suppressor protein neurofibromin in normal human wound healing and in vitro evidence for platelet derived growth factor (PDGF) and transforming growth factor β1 (TGFβ1) elicited increase in neurofibromin mRNA steady-state levels in dermal fibroblasts. J Invest Dermatol 1998; 110: 232-7.
31. Wallace MR, Marchuk DA, Andersen LB et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990; 249: 181-6.
32. Eckert R, Crish JF, Robinson NA. The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation. Physiol Rev 1997; 77: 397-424.
33. Koivunen J, Ylä-Outinen H, Korkiamäki T et al. New function for NF1 tumor suppressor. J Invest Dermatol 2000; 114: 473-9.
34. DeClue JE, Cohen BD, Lowy DR. Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci USA 1991; 88: 9914-18.
35. Basu TN, Guttman DH, Fletcher JA et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356: 713-15.
36. Adjei AA. Ras signaling pathway proteins as therapeutic targets. Curr Pharm Des 2001; 7: 1581-94.
37. Zhu Y, Parada LF. Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res 2001; 264: 19-28.
38. Mercer JA. Intercellular junctions: downstream and upstream of Ras? Semin Cell Dev Biol 2000; 11: 309-14.
39. Korkiamäki T, Ylä-Outinen H, Koivunen J et al. Altered calcium-mediated cell signaling in keratinocytes cultured from patients with neurofibromatosis type 1. Am J Pathol 2002; 160: 1981-90.